Among the various parameters considered essential for selecting first‐line treatment in metastatic ccRCC, international experts have highlighted the importance of PD‐L1 status alongside the IMDC risk group [30]. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.